 Approximately 70 of women with breast cancer experience behavioral andor cognitive symptoms during treatment with chemotherapy and approximately 30 of women continue to experience these symptoms months to years after treatment completion. There is mounting data to suggest that inflammation may be involved and indicate that chemotherapy-treated breast cancer patients exhibit higher inflammatory markers than non-chemotherapy-treated patients, and inflammatory markers including interleukin IL-6 and soluble tumor necrosis factor sTNFR2 have been associated with chemotherapy-induced depression and fatigue. 